Insilico Medicine
AI drug-discovery company using artificial intelligence to accelerate pharmaceutical research and development
Our Take
The $2.75 billion collaboration Insilico just locked in with Eli Lilly is honestly huge — that's not a "we believe in you" angel round, that's one of the world's largest pharma companies saying their AI platform for drug discovery is legit. Founded back in 2014 out of Baltimore, they've been low-key building one of the most mature pipelines in generative AI-driven biotech, which is why a company like Lilly just handed them the kind of deal most AI drug startups never see. The real signal here is that Insilico isn't just theorizing about accelerating R&D — they have the proof of concept and the check to back it up.
Key Facts
The people behind Insilico Medicine
Links
Similar products worth knowing
Ludii
An AI-supported system used by researchers to simulate and test possible rule sets for ancient board games. Used in arch
Rivet
Open-source operating system for AI agents with ~6ms cold starts and 32x cheaper than sandboxes.
Moonshot AI (Kimi)
Chinese AI startup behind the Kimi AI assistant, with Kimi K2.5 being one of the top open models competing with Gemma 4
Sakana AI
Japanese AI startup developing hypernetwork methods for instant LoRA 'compilation' - Doc-to-LoRA and Text-to-LoRA genera
Want products like this in your inbox every morning?
Five products. Every morning. Written by someone who actually cares whether they're good or not. Free forever, unsubscribe whenever.